What did Iperion Limited announce?
Iperion Limited (NZX: IPR) filed “2026 Annual Meeting Presentation Material” with NZX on 30 September 2026, as an agm announcement.
From the announcement:“For shareholders who have not voted yet via MUFG, but still wish to do so after the meeting, please forward your completed voting form to john.cilliers@iperion.co.nz by no later than 4pm today.”
- Which company?
- Iperion Limited (NZX: IPR)
- When was it filed?
- 30 September 2026
- Where is the original?
- NZX announcement
2026 Annual Meeting Presentation Material
Iperion Limited
Annual Meeting
30 September 2026
Agenda
•
Welcome and Introductions
•
Formalities
•
Presentation to Shareholders
•
Q&A Discussion
•
Resolutions
•
Appendix: Additional information on Pathoglaze
Formalities
•
Attendance of the virtual meeting has been left open for all
interested to be able to attend.
•
The meeting is recorded.
•
To ensure that voting is accounted for correctly, all votes will
be required to be submitted electronically. For shareholders
who have not voted yet via MUFG, but still wish to do so after
the meeting, please forward your completed voting form to
john.cilliers@iperion.co.nz by no later than 4pm today.
(contact John if you need a form)
Review of the year ended 31 March 2026
•
No interest income in 2026 as cash was
not placed in term deposits so as to be
available to cover costs for an
anticipated sales order.
•
Fixed outsource manufacturing plant fee
fully discounted for 2026.
•
Admin expenses lower in 2026 with
savings made in travel costs and audit
fees. Savings were partially offset by
increase in stock exchange fees.
•
Impairment expense was on trademark
intangibles. There were no costs for
trademarks in 2026.
•
There were no changes in the number
of shares on issue.
2025
$
2026
$
20,38210Interest income
150,0000
Outsource
Manufacturing Plant
317,781294,605Administrative expenses
8,2840Impairment expense
455,683294,595Net loss
348,39853,803Net assets
425,341155,492Cash and Term deposits
Cash Reserves and Financial Support
Financial support:
The Company entered into a loan agreement with Elitesoft Asia, a company
related to Mr Chang Ku EE, the majority shareholder and a director of the
Company, pursuant to which Elitesoft provides a loan facility of $250,000 to
the Company at 8% interest (Hong Kong Monetary Authority Base Rate + 4%),
which can be increased to US$1,000,000 subject to approval by Iperion’s
shareholders.
Mr EE confirmed that he will provide financial support to the Company, if
required to meet its working capital obligations and liabilities as they fall due,
for at least a period of 12 months from the date of approval of the Company’s
financial statements (30 Jun 2026).
Initiatives to conserve cash reserves:
Since January 2026, payment on 50% of directors’ fees and 33% of the
management fee are being deferred, until sufficient sales are achieved to
move the company to a positive cash flow position.
Manufacturing Facilities
Outsource Manufacturing Plant:
The fixed annual fee on the Pathoglaze outsource manufacturing plant fees for
the financial year to March 2026 was fully discounted by the vendor and will
be fully discounted through to March 2028.
The vendor is in the process of moving the manufacturing plant from Malaysia
to Singapore. The equipment is currently in storage. Sufficient Pathoglaze
compound has already been manufactured and is available to fill sales orders
until the plant is setup again. In the interim, ongoing product development is
being supported from the Licensor’s facilities in Singapore where smaller
product batches can also be manufactured if needed.
In recognition of the collaborative efforts undertaken between the inventor of
Pathoglaze and Iperion, agreement was reached to permanently waive the
customer and revenue performance targets under Iperion’s exclusive world-
wide license.
Progress and current activities
Work undertaken during the year ending March 2026 mainly focused on
completing the development of Pathoglaze infused polymer jute bags
used for shipping cocoa and coffee beans. This work was being
undertaken in collaboration with a multinational chocolate manufacturer
Product tests and trials for specific applications continue with potential
customers as they arise.
With support from Mr EE, directors have also been investigating a range
of alternative product and sales opportunities for the company.
Questions
Resolution 1
John Cilliers retires by rotation in accordance with the Company’s constitution and
NZX
Listing Rule 2.7.1
. Being eligible, John offers himself for re-election. The Board considers
John to be an Independent Director. Accordingly, the shareholders of the Company are
requested to consider and, if thought fit, pass the following resolution as an Ordinary
Resolution.
Ordinary Resolution: That that John Cilliers, who retires in accordance with NZX Listing
Rule 2.7.1, and being eligible for re-election, be re-elected as a director of IPR.
Abstain
% of Issued
Capital
AgainstOpenFor
0
78.98%9,0004,000406,661,251
Votes
143Holders
0.00%0.00%100.00%
Percentage
Proxies:
Resolution 2
Kuan Chong Ng (“KC”), retires by rotation in accordance with the Company’s constitution.
Being eligible, KC offers himself for re-election at the Annual Meeting. The Board does not
consider Mr Ng to be an Independent Director. Accordingly, the shareholders of the Company
are requested to consider and, if thought fit, pass the following resolution as an Ordinary
Resolution.
Ordinary Resolution: That Kuan Chong Ng, who retires in accordance with NZX Listing Rule
2.7.1, and being eligible for re-election, be re-elected as a director of IPR.
Abstain
% of Issued
Capital
AgainstOpenFor
0
78.98%9,0004,000406,661,251
Votes
143Holders
0.00%0.00%100.00%
Percentage
Proxies:
Resolution 3
BDO is automatically reappointed at the annual meeting as the auditor of the Company
under section 207T of the Companies Act. This resolution authorises the Board to fix the
fees and expenses of the auditor.
Ordinary Resolution: That the Board is authorised to fix BDO Auckland’s fees and
expenses as the auditor of IPR.
Abstain
% of Issued
Capital
AgainstOpenFor
398,528,343
1.58%04,0008,141,908
Votes
043Holders
0.00%0.05%99.95%
Percentage
Proxies:
Thank you
Pathoglaze is a durable, high potency, anti-
microbial product capable of being
incorporated into raw materials for other
products at the point of manufacture.
For example it can be incorporated in plastics
masterbatch powders prior to product
moulding or it can be applied to existing
products as a thin film coating.
•
Pathoglaze infused polymer jute bags
used for shipping cocoa and coffee
beans.
•
These bags reduce losses that result
from microbial contamination during
shipping and transport.
PATHOGLAZE®Hyperion is a high-potency zinc-basedantimicrobial additive.
Having a core shell- nanopillar morphological structure.
It can kill, reduce and prevent the growth of harmful microorganism (e.g.: bacteria,
virus, fungi, algae).
Having an antimicrobial activity up to 99.9 % (test method: ISO22196).
Can be seamlessly incorporated in a wide range of end-use products during
the manufacturing process without interfering with the actual manufacturing
setup.
HYPERIONAdditive
–greyish powder
Fine Powder (Additives)
UNIQUE MECHANISM
Does not rely on external
stimulus light energy to
generate ROS.
SAFETY
Safe to be used as additive in
food packaging polymers.
*Tested in compliance with
US FDA and EU regulation.
EFFICACY
99.9 % effective against
microorganisms, even
at low use levels.
STABILITY
It has thermal resistance
up to 410 °C and is
insoluble in water.
FLEXIBILITY
Seamless incorporation
into a wide range of
applications.
Key Features
Additives
PATHOGLAZE
PLASTICS AND POLYMERS
(Food-grade and non food-grade)
List of polymers compatible with PATHOGLAZE:
i. Commodity thermoplastics (i.e.: PE, PS)
ii. Engineering thermoplastics (i.e.: PC, ABS, PC/ABS,
PA)
iii. Thermosets (i.e.: epoxy)
iv. Synthetic rubber (i.e.: NBR and EPDM)
PAINTS AND COATINGS
By Applications
Area of Application
PATHOGLAZE®
Our PATHOGLAZE®additives are compatible with almost all plastics and
polymer materials (i.e.: trial for PP, PC and ABS).
With 0.5%of PATHOGLAZE loading = 99.9%of antimicrobial activity
(ISO22196)
Seamlessly compound in polymer using the existing process
Embedded within the polymer compound itself, delivering continuous
protection against microbes without affecting gloss or matte surfaces, color,
durability, and properties.
PP compound with 0.5% of
PATHOGLAZE
PASS
In-polymer Food Contact Test according to
-US FDA 21 CFR 177.1520
PASS
Migration Test according to Commission Regulation (EU)
-EU 10/2011 Article 3 of European Regulation
1935/2004*
Polymer compound
P o t e n t i a l
PATHOGLAZE
APPLICATION
Cutting boards, wall coverings, appliances,
toilet seats, flooring, mattresses
Housewares:
PVC blinds, car interiors, packaging, signs,
electronics, seating
Commercials:
yoga mats, footwear, duffle bags,
sports equipment
Fitness:
flooring, vinyl siding, windows, insulation,
piping, roofing membranes
Construction materials:
business supplies, medical devices, seating,
countertops, storage
Healthcare:
i. Prevents the growth of bacteria and fungi on the surface.
ii. Reduces bacteria in the surrounding area, and reduces the spread of infection.
iii. Prolongs food shelf life.
iv. Promotes product reusability and recyclability.
Packaging (primary & secondary)
Thin film is a layer of material with a thickness ranging from a
nanometer to micrometer on the surface of a substrate.
Harnessing the potential of zinc, PATHOGLAZE thin film is a
zinc-based thin-film coating.
PATHOGLAZE
®
thin film series is particularly targeted for
coating on non-porous surfaces i.e.; glass windows, solar
panels, touch-sensitive displays, etc. where transparency
coating is a key consideration.
Thin Film
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PHL — Promisia Healthcare Limited: ASM 2026 Presentation2026-08-27
“1 Annual Shareholders’ Meeting 27 August 2026 2 Board Rhonda Sherriff Chair and Independent Director Thomas Brankin Non-Independent Director 1 Tony Mortensen Non-Independent Director Jill Hatchwell Independent Director Craig Percy Independent Director Francisco Rodriguez Ferrer…”
- RUA — Rua Bioscience Limited: Rua Releases Annual Report for Year Ended 30 June 20262026-09-22
“74Financial statements Research and Development (R&D) Loss Tax Credit repayment The Company claimed R&D Loss Tax Credits in the 2019 and 2020 income years under the Income Tax Act 2007. Under the Act, these credits become repayable in certain circumstances where shareholder con…”
- IPL — Investore Property Limited: Interim Results HY272026-11-16
“Corporate Directory Board of Directors Mike Allen (Chair) Gráinne Troute Adrian Walker Ross Buckley (SIML-appointed Director) D avid Green (SIML-appointed Director, appointed 3 June 2026) T im Storey (SIML-appointed Director, ceased 3 June 2026) Registered Office L evel…”